Post-Approval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States–Based Rheumatoid Arthritis Registry
ACR Open Rheumatol. 2021 Feb 11.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
ACR Open Rheumatol. 2021 Feb 11.
Arthritis Res Ther. 2021;23(1):53.
Ann Rheum Dis 2021;80:96–102.
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992
Annals of the Rheumatic Diseases 05 August 2020 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.
Arthritis Res Ther 2020;22:142
RMD Open 2020;6:e001174 doi:10.1136/rmdopen-2020-001174
Drug Saf. 2020;43:379-392
Immunotherapy. 2019 Mar;11(4):321-333.
Desai RJ, et al. Arthritis Rheumatol. 2019 June;71(6):892-900.